Vanda Pharmaceuticals
VNDA · Nasdaq · United States
Share price · VNDA
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when VNDA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 3 Nov 2026-3.4%
- 30 Oct 2026-6.4%
Nothing announced by VNDA that day or the session before.
- 12 Aug 2026+5.3%
Nothing announced by VNDA that day or the session before.
- 5 Aug 2026-4.5%
- 20 Mar 2026-16.9%
- 23 Feb 2026+41.5%
- 12 Feb 2026-17.6%
- 31 Dec 2025+25.5%
- 10 Dec 2025+11.4%
Nothing announced by VNDA that day or the session before.
- 8 Dec 2025+13.9%
Nothing announced by VNDA that day or the session before.
Share of unusual movement by asset
For each asset, the share of VNDA's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(6 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Small molecule | SchizophreniaBipolar Disorder | |
| Approved | Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Small molecule | Major Depressive DisorderSchizophreniaBipolar Disorder | |
| Approved | S1P receptorSmall molecule | Inflammatory Bowel DiseasePsoriasisMultiple Sclerosis Ulcerative Colitis | |
tasimelteon(Hetlioz) | Approved | Melatonin receptor (MT1/MT2)Small molecule | Non-24-Hour Sleep-Wake Disorder |
| Phase 3 | IL-36 receptorMonoclonal antibody | Psoriasis | |
| Phase 3 | Neurokinin-1 (NK1) receptorSmall molecule | Gastroparesis |
Upcoming events
(7 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
2027 (3)
2028 (2)
March 2028 (1)
What to watch
Regulatory and conference events
(19)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent
The 12 most recent of 18 past events are shown.
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $70M | $28M | $62M+ $79M short-term inv. | $23M-$28M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $51M | $37M | $56M+ $114M short-term inv. | $63M-$31M operating cash flow | report ↗ |
| 2026-Q1 | $52M | $28M | $202M | $49M | report ↗ |
| 2025-Q3 | $56M | $23M | $70M+ $224M short-term inv. | $23M-$32M operating cash flow | report ↗ |
| 2025-Q2 | $53M | $22M | $81M+ $245M short-term inv. | $27M-$15M operating cash flow | report ↗ |
| 2025-Q1 | $50M | $36M | $112M+ $229M short-term inv. | $29M-$33M operating cash flow | report ↗ |
| 2024-Q3 | $48M | $17M | $101M+ $276M short-term inv. | $5.3M-$15M operating cash flow | report ↗ |
| 2024-Q2 | $50M | $17M | $103M+ $285M short-term inv. | $4.5M-$6.9M operating cash flow | report ↗ |
| 2024-Q1 | $47M | $21M | $126M+ $269M short-term inv. | $4.2M$7.6M operating cash flow | report ↗ |
| 2023-Q3 | $39M | $17M | $184M+ $307M short-term inv. | —-$2.0M operating cash flow | report ↗ |
| 2023-Q2 | $46M | $17M | $151M+ $339M short-term inv. | —-$13M operating cash flow | report ↗ |
| 2023-Q1 | $63M | $19M | $355M+ $147M short-term inv. | —$32M operating cash flow | report ↗ |
| 2022-Q3 | $65M | $25M | $50M+ $405M short-term inv. | —$13M operating cash flow | report ↗ |
| 2022-Q2 | $64M | $21M | $59M+ $383M short-term inv. | —$5.7M operating cash flow | report ↗ |
| 2022-Q1 | $60M | $21M | $67M+ $368M short-term inv. | $6.4M$4.0M operating cash flow | report ↗ |
| 2021-Q3 | $70M | $20M | $51M+ $355M short-term inv. | —$9.4M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $216M | $109M | $85M+ $179M short-term inv. | $55M-$109M operating cash flow | report ↗ |
Vanda reported FY2025 revenue of $216.11M, up 8.7% YoY from $198.77M, with R&D spend of $109.27M, up 46.8% YoY. Cash and equivalents were $85.32M, and the company reported a net loss of $220.47M, with quarterly net burn of $220.47M.
During the year, NEREUS (tradipitant) was approved in the U.S. for prevention of vomiting induced by motion; the Bysanti (milsaperidone) NDA for bipolar I disorder and schizophrenia was accepted with a PDUFA date of February 21, 2026. The company also highlighted ongoing Phase III programs for Fanapt long-acting injectable, Bysanti in major depressive disorder, and HETLIOZ in delayed sleep phase disorder, along with development of imsidolimab and other pipeline assets. In October 2025, Vanda entered a collaborative framework with the FDA regarding certain HETLIOZ and NEREUS disputes, and in January 2026 the FDA indicated the HETLIOZ jet lag sNDA could not be approved in its current form.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $199M | $74M | $103M+ $272M short-term inv. | $4.7M-$16M operating cash flow | report ↗ |
| 2023-FY | $193M | $77M | $136M+ $252M short-term inv. | —$13M operating cash flow | report ↗ |
| 2022-FY | $254M | $86M | $136M+ $332M short-term inv. | —$32M operating cash flow | report ↗ |
| 2021-FY | $269M | $75M | $53M+ $381M short-term inv. | —$64M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 3 purchases ($38K), 6 sales ($2.8M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-05 | Duncan Charles Cliff · director | Open-market purchase | 5,803 | $3.80 | $22K | Form 4 |
| 2026-11-04 | Duncan Charles Cliff · director | Open-market purchase | 3,447 | $3.82 | $13K | Form 4 |
| 2026-11-03 | Duncan Charles Cliff · director | Open-market purchase | 750 | $3.80 | $3K | Form 4 |
| 2026-06-04 | Mitchell Stephen Ray · director | Award / grant | 41,600 | — | — | Form 4 |
| 2026-06-04 | Honore Tage · director | Award / grant | 41,600 | — | — | Form 4 |
| 2026-06-04 | Ward Anne Sempowski · director | Award / grant | 41,600 | — | — | Form 4 |
| 2026-06-04 | DUGAN RICHARD W · director | Award / grant | 41,600 | — | — | Form 4 |
| 2026-06-04 | Duncan Charles Cliff · director | Award / grant | 41,600 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 169 reporting institutions held 46.2M shares ($295.5M, 76.4% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 7,275,988 | $50.3M |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 3,759,559 | $26.0M |
| 3 | STATE STREET CORP | 3,015,562 | $20.8M |
| 4 | AIGH Capital Management LLC | 2,750,000 | $19.0M |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 2,481,491 | $17.1M |
| 6 | MILLENNIUM MANAGEMENT LLC | 1,881,001 | $13.0M |
| 7 | DIMENSIONAL FUND ADVISORS LP | 1,771,593 | $12.2M |
| 8 | AQR CAPITAL MANAGEMENT LLC | 1,603,576 | $11.1M |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 1,442,965 | $10.0M |
| 10 | TWO SIGMA INVESTMENTS, LP | 1,398,201 | $9.7M |
| 11 | JACOBS LEVY EQUITY MANAGEMENT, INC | 1,168,681 | $8.1M |
| 12 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1,014,522 | $7.0M |
| 13 | Empire Financial Management Company, LLC | 922,245 | $6.4M |
| 14 | GOLDMAN SACHS GROUP INC | 838,233 | $5.8M |
| 15 | CITADEL ADVISORS LLC | 633,354 | $4.4M |